CuroNZ
Curonz is a clinical stage biotechnology company focused on developing groundbreaking neurotherapeutic drugs for severe neurological diseases. Their mission is to create effective treatments that improve the quality of life for patients with conditions like epilepsy, neurodegenerative diseases, and other CNS disorders. They aim to contribute to scientific knowledge in neuronal regeneration and develop therapies for hard-to-treat CNS diseases.
Industries
Nr. of Employees
small (1-50)
CuroNZ
Registered offices in USA, Western Australian and New Zealand (Ruakura Campus, Hamilton).
Patents
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
US-7767786-B2
View Details
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
US-7767786-B2
View DetailsProducts
Clinical-stage peptide therapeutic platform (neural regeneration peptides)
A platform of synthetic peptide/peptidomimetic drug candidates with demonstrated preclinical neuroregenerative, neuroprotective and anticonvulsant activity; includes a clinical lead developed for refractory epilepsy indications.
Clinical-stage peptide therapeutic platform (neural regeneration peptides)
A platform of synthetic peptide/peptidomimetic drug candidates with demonstrated preclinical neuroregenerative, neuroprotective and anticonvulsant activity; includes a clinical lead developed for refractory epilepsy indications.
Expertise Areas
- Clinical trial management for early-stage neurotherapeutics
- Peptide and peptidomimetic drug discovery
- Preclinical efficacy testing in neurological disease models
- Neuropharmacology and electrophysiology
Key Technologies
- Organotypic brain-slice and microexplant phenotypic assays
- Rodent translational disease models (GAERS, pilocarpine, PTZ, SOD1-G93A, MOG-EAE, optic nerve ligation, pyridoxine PN)
- Peptide synthesis and peptidomimetic medicinal chemistry
- Subcutaneous injectable and topical ophthalmic formulation